Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) will present clinical results from its ongoing Phase 1b trial of intratumoral INTASYL PH-762 at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 7-9, 2025.

The poster (Abstract #610) titled "PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: A Clinical Study of INTASYL PH-762" will be presented by Mary Spellman, M.D. on Saturday, November 8, 2025 at the Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.

The Phase 1b dose-escalation study evaluates safety and tolerability of intratumoral PH-762 in patients with cutaneous squamous carcinoma, Merkel cell carcinoma, and melanoma.

Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Maryland from November 7-9, 2025.

Phio's poster presentation will highlight the clinical results from the ongoing Phase 1b dose escalation clinical trial. This clinical trial is designed to evaluate the safety and tolerability of intratumoral injection of PH-762 in patients with cutaneous squamous carcinoma, Merkel cell carcinoma, and melanoma.

Presentation Details are as follows:

	Title:	PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: A Clinical Study of INTASYL PH-762
	Abstract Number:	610
	Presenting Author:	Mary Spellman, M.D.
	Date:	Saturday November 8, 2025
	Location:	Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center

 

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL^® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The ongoing Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, our expectations with respect to the continued safety results of our clinical trial, our expectations with respect to the potential of a well-tolerated treatment for cutaneous carcinomas, and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.  

These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.  

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273523

FAQ

When will Phio Pharmaceuticals (PHIO) present PH-762 data at SITC 2025?

The PH-762 poster (Abstract #610) will be presented on Saturday, November 8, 2025.

What Phase is the PH-762 trial that Phio (PHIO) is presenting at SITC?

Phio will present results from an ongoing Phase 1b dose-escalation clinical trial.

Which cancers are included in Phio's PH-762 Phase 1b study (PHIO)?

The trial enrolls patients with cutaneous squamous carcinoma, Merkel cell carcinoma, and melanoma.

Where and how can investors see Phio's (PHIO) SITC presentation details?

The poster will be at Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center, National Harbor, Maryland on November 8, 2025.

Who is the presenting author for Phio's PH-762 poster at SITC 2025?

The presenting author is Mary Spellman, M.D. for Abstract #610.

What does Phio's PH-762 SITC poster evaluate in its study design?

The poster highlights a dose-escalation study designed to evaluate the safety and tolerability of intratumoral PH-762.